Biomarkers related to treatment of cancer with her3 and egfr inhibitors 机翻标题: 暂无翻译,请尝试点击翻译按钮。

公开号/公开日
WO2016168634 A1 2016-10-20 [WO2016168634] / 2016-10-20
申请号/申请日
2016WO-US27802 / 2016-04-15
发明人
LAVALLEE THERESA MARIE;ALVARADO DIEGO;
申请人
BULLDOG PHARMACEUTICALS;
主分类号
IPC分类号
A61K-039/395C07H-021/04C07K-016/00
摘要
(WO2016168634) Provided herein are methods of treating cancers expressing specific biomarkers with HER3 and/or EGFR inhibitors, and provided herein are also biomarkers and uses thereof in determining likelihood of effective cancer treatment with HER3 and/or EGFR inhibitors.  In one aspect, the disclosure provides methods for treating a cancer, comprising administering to a patient diagnosed with said cancer a therapeutically effective amount of a HER3 inhibitor, an EGFR inhibitor, or a combination of a HER3 inhibitor and an EGFR inhibitor.  Also disclosed herein are kits comprising components for performing the methods for determining whether a patient diagnosed with cancer is indicated as likely to be responsive to treatment with a HER3 inhibitor and/or an EGFR inhibitor.
机翻摘要
暂无翻译结果,您可以尝试点击头部的翻译按钮。
地址
代理人
代理机构
;
优先权号
2015US-62149474 2015-04-17 2015US-62175135 2015-06-12 2015US-62251076 2015-11-04
主权利要求
(WO2016168634)  1. A method of treating a cancer, comprising administering to a patient diagnosed with said cancer a therapeutically effective amount of a HER3 inhibitor, an EGFR inhibitor, or a combination of a HER3 inhibitor and an EGFR inhibitor, wherein the patient has a tumor that has been characterized in that cells from the tumor: i) express a neuregulin, and ii) express high levels of one or more of amphiregulin (AREG), TGF-a, and EGFR homodimer.  57. A method of determining whether a patient diagnosed with cancer is indicated as likely to be responsive to treatment with a HER3 inhibitor, an EGFR inhibitor, or a combination of a HER3 inhibitor and an EGFR inhibitor, comprising measuring the expression of one or more of AREG, TGF-a, and EGFR homodimer in a sample from the patient, wherein the sample comprises tumor cells and a neuregulin, and wherein high levels of one or more of AREG, TGF-a, and EGFR homodimer in the sample indicates that the patient is likely to be responsive to treatment with a FIER3 inhibitor, an EGFR inhibitor, or a combination of a FIER3 inhibitor and an EGFR inhibitor.  58. A method of determining whether a patient diagnosed with cancer is indicated as likely to be responsive to treatment with a FIER3 inhibitor, an EGFR inhibitor, or a combination of a FIER3 inhibitor and an EGFR inhibitor, comprising measuring the expression of a neuregulin, and at least one of AREG, TGF-a, and EGFR homodimer in a sample from the patient, wherein the sample comprises tumor cells, and wherein the presence of the neuregulin and high levels of one or more of AREG, TGF-a, and EGFR homodimer in the sample indicates that the patient is likely to be responsive to treatment with a FIER3 inhibitor, an EGFR inhibitor, or a combination of a HER3 inhibitor and an EGFR inhibitor.  125. A method of treating a cancer, comprising administering to a patient diagnosed with said cancer a therapeutically effective amount of a HER3 inhibitor, an EGFR inhibitor, or a combination of a HER3 inhibitor and an EGFR inhibitor, wherein the patient has a tumor that has been characterized in that cells from the tumor express high levels of EGFR homodimer.  168. A method of determining whether a patient diagnosed with cancer is indicated as likely to be responsive to treatment with a FIER3 inhibitor, an EGFR inhibitor, or a combination of a FIER3 inhibitor and an EGFR inhibitor, comprising measuring the expression of at least one of AREG, TGF-a, and EGFR homodimer in a sample from the patient, wherein the sample comprises tumor cells, and high levels of one or more of AREG, TGF-a, and EGFR homodimer in the sample indicates that the patient is likely to be responsive to treatment with a FIER3 inhibitor, an EGFR inhibitor, or a combination of a FIER3 inhibitor and an EGFR inhibitor.  231. A method of treating a cancer, comprising administering to a patient diagnosed with said cancer a therapeutically effective amount of (i) a HER3 inhibitor, (ii) a combination of a HER3 iinhibitor and a B-Raf inhibitor, (iii) a combination of a HER3 inhibitor and a MEK inhibitor, or (iv) a combination of a HER3 inhibitor, a B-Raf inhibitor, and a MEK inhibitor, wherein the patient has a tumor that has been characterized in that cells from the tumor express a neuregulin.  303. A method of determining whether a patient diagnosed with cancer is indicated as likely to be responsive to treatment with (i) a HER3 inhibitor, (ii) a combination of a HER3 inhibitor and a B-Raf inhibitor, (iii) a combination of a HER3 inhibitor and a MEK inhibitor, or (iv) a combination of a HER3 inhibitor, a B-Raf inhibitor, and a MEK inhibitor, comprising measuring the expression of a neuregulin, wherein high levels of the neuregulin in the sample indicates that the patient is likely to be responsive to treatment with (i) a HER3 inhibitor, (ii) a combination of a HER3 inhibitor and a B-Raf inhibitor, (iii) a combination of a HER3 inhibitor and a MEK inhibitor, or (iv) a combination of a HER3 inhibitor, a B-Raf inhibitor, and a MEK inhibitor.
法律状态
(WO2016168634) LEGAL DETAILS FOR WO2016168634  Actual or expected expiration date=2018-10-17    Legal state=ALIVE    Status=PENDING     Event publication date=2016-04-15  Event code=WO/APP  Event indicator=Pos  Event type=Examination events  Application details  Application country=WO WOUS2016027802  Application date=2016-04-15  Standardized application number=2016WO-US27802     Event publication date=2016-10-20  Event code=WO/A1  Event type=Examination events  Published application with search report  Publication country=WO  Publication number=WO2016168634  Publication stage Code=A1  Publication date=2016-10-20  Standardized publication number=WO2016168634  LEGAL DETAILS FOR DESIGNATED STATE EP  Actual or expected expiration date=2035-04-17    Legal state=ALIVE    Status=PENDING   Corresponding cc:  Designated or member state=EP Corresponding appl: EP16780859    Event publication date=2016-11-30  Event code=WO/121  Event type=Designated states  EP: The EPO has been informed by wipo that ep was designated in this application Corresponding cc:  Designated or member state=EP
专利类型码
A1
国别省市代码
若您需要申请原文,请登录。

最新评论

暂无评论。

登录后可以发表评论

意见反馈
返回顶部